Trials / Recruiting
RecruitingNCT06657846
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome
Health-Related Quality of Life and Financial Toxicity in Patients With VEXAS Syndrome: An Italian GIMEMA Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This multicenter cross-sectional observational study aims to describe health-related quality of life (HRQoL) and symptom profiles of patients with VEXAS syndrome.
Detailed description
Moreover, the study will investigate financial toxicity and treatment tolerability. To contextualize the results the data of VEXAS patients will be compared with a cohort of matched MDS patients. The overall aim of the study is to establish benchmark HRQoL data to be used in future prospective studies and clinical trial design.
Conditions
Timeline
- Start date
- 2024-11-01
- Primary completion
- 2025-06-10
- Completion
- 2025-09-10
- First posted
- 2024-10-26
- Last updated
- 2025-07-15
Locations
17 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT06657846. Inclusion in this directory is not an endorsement.